High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Wang, Chunyu, Fu, Xiaolong, Cai, Xuwei, Wu, Xianghua, Hu, Xichun, Fan, Min, Xiang, Jiaqing, Zhang, Yawei, Chen, Haiquan, Jiang, Guoliang, Zhao, Kuaile
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4699509/
https://ncbi.nlm.nih.gov/pubmed/26766917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S89592
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak